Insulin-like Growth Factor II mRNA-Binding Protein 3 Expression in Benign and Premalignant Lesions and Carcinomas of the Stomach.
- Author:
Dae Hyun SONG
1
;
Jung Wook YANG
;
Dong Chul KIM
;
Jong Sil LEE
;
Jeong Hee LEE
;
Sang Ho JEONG
;
Gyung Hyuck KO
Author Information
1. Department of Pathology, Gyeongsang National University School of Medicine, Jinju, Korea. gyunghko@gnu.ac.kr
- Publication Type:Original Article
- Keywords:
Stomach;
Carcinoma;
Adenoma;
IMP3 protein
- MeSH:
Adenoma;
Humans;
Insulin-Like Growth Factor II;
Neoplasm Metastasis;
Prognosis;
Risk Factors;
Stomach
- From:Korean Journal of Pathology
2011;45(4):379-385
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Recent studies have demonstrated that insulin-like growth factor II mRNA-binding protein 3 (IMP3) is expressed in malignant tumors of various organs but not in normal tissue. We investigated IMP3 expression in various benign lesions, premalignant lesions and carcinomas of the stomach. METHODS: IMP3 immunohistochemical staining was performed on 24 benign gastric lesions, 24 gastric adenomas, and 322 gastric carcinomas. RESULTS: IMP3 was not expressed in benign gastric lesions including adenomas with low-grade dysplasia, but was expressed in 17% of adenomas with high-grade dysplasia, and in 44% of carcinomas. As the carcinomas were in the advanced stage, they expressed IMP3 more frequently and strongly. Patients with IMP3-positive tumors had poorer survival than those with negative tumors. CONCLUSIONS: IMP3 expression in gastric carcinoma may be related to tumor invasion and metastasis, and is an independent risk factor for poor prognosis.
